Venus Medtech (Hangzhou), Inc. Class H (HK:2500) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Venus Medtech (Hangzhou) Inc. successfully conducted its 2024 first extraordinary general meeting and class meetings, wherein all resolutions, except for two, were passed. The meetings saw a 12.93% attendance of the total issued share capital, with key decisions including the appointment of a new Supervisor and approval of amendments to company rules and procedures. The results reflect shareholder support and compliance with PRC laws and corporate statutes.
For further insights into HK:2500 stock, check out TipRanks’ Stock Analysis page.